Physician profile
John Santos
NPI 1649762352
$7,329.93
in general payments reported to CMS, 2019-2025
28 companies · $1,125 in 2025
The $1,125 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,420 · 2022: $1,896 · 2023: $1,426 · 2024: $1,464 · 2025: $1,125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,014.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,014.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,160.33 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $1,119.13 | 2021-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $752.36 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $626.02 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $554.75 | 2022-2025 | Ingrezza |
| Corium, LLC | $401.31 | 2022-2025 | Azstarys |
| Lundbeck LLC | $322.64 | 2021-2025 | Rexulti, Abilify Asimtufii |
| Supernus Pharmaceuticals, INC. | $319.30 | 2022-2025 | Qelbree, Qelbree |
| Axsome Therapeutics, INC. | $302.77 | 2022-2025 | Auvelity |
| Alkermes, INC. | $280.16 | 2021-2024 | Aristada, Lybalvi |
| Takeda Pharmaceuticals U.S.A., INC. | $222.48 | 2021-2025 | Trintellix |
| Tris Pharma INC | $202.53 | 2022-2025 | Dyanavel Xr |
| Teva Pharmaceuticals USA, INC. | $201.64 | 2022-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Acadia Pharmaceuticals INC | $168.14 | 2021 | |
| Vanda Pharmaceuticals INC. | $145.23 | 2021-2025 | Fanapt, Hetlioz |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $118.54 | 2025 | Cobenfy |
| Ironshore Pharmaceuticals INC. | $77.09 | 2024 | |
| Sunovion Pharmaceuticals INC. | $48.38 | 2021-2022 | |
| Orexo US, INC. | $47.04 | 2021-2022 | |
| Indivior INC. | $44.76 | 2022-2025 | Sublocade |
| Idorsia Pharmaceuticals US INC | $40.65 | 2023 | Quviviq |
| Noven Therapeutics, LLC | $35.08 | 2024 | Xelstrym, Secuado |
| Collegium Pharmaceutical, INC. | $34.75 | 2025 | Jornay Pm |
| Avanir Pharmaceuticals, INC. | $23.84 | 2021 | |
| Neos Therapeutics, LP | $23.41 | 2024 | Adzenys Xr-Odt |
| Bausch Health US, LLC | $22.70 | 2023 | Aplenzin |
| Tempus Ai, INC | $20.55 | 2024 | |
| Biogen, INC. | $14.35 | 2025 | Zurzuvae |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Santos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.